Aquestive Therapeutics rises after pricing $85M stock offering

* Aquestive Therapeutics (NASDAQ:AQST [https://seekingalpha.com/symbol/AQST]) has priced [https://seekingalpha.com/pr/20200635-aquestive-therapeutics-announces-pricing-of-85-million-underwritten-offering-of-common-stock]an underwritten offering of 21.25M shares at $4.00 each, expecting $85M in gross proceeds.
* Funds will mainly support the potential launch and commercialization of Anaphylm (epinephrine) Sublingual Film for severe allergic reactions, pending FDA approval, as well as for general corporate purposes.
* Closing is expected around August 15, 2025.
* Shares rose 7.2% premarket.

MORE ON AQUESTIVE THERAPEUTICS

* Aquestive Therapeutics, Inc. 2025 Q2 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4812599-aquestive-therapeutics-inc-2025-q2-results-earnings-call-presentation]
* Aquestive Therapeutics, Inc. (AQST) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4812597-aquestive-therapeutics-inc-aqst-q2-2025-earnings-call-transcript]
* Aquestive Therapeutics: Updating The Anaphylm Timeline To Approval [https://seekingalpha.com/article/4797134-aquestive-therapeutics-updating-the-anaphylm-timeline-to-approval]
* Aquestive outlines patient-first Anaphylm launch strategy and maintains 2025 revenue guidance amid FDA review progress [https://seekingalpha.com/news/4483956-aquestive-outlines-patient-first-anaphylm-launch-strategy-and-maintains-2025-revenue-guidance]
* Aquestive Therapeutics GAAP EPS of -$0.14 beats by $0.03, revenue of $10M misses by $1.32M [https://seekingalpha.com/news/4483399-aquestive-therapeutics-gaap-eps-of-0_14-beats-by-0_03-revenue-of-10m-misses-by-1_32m]